Drugs / CD19.CAR/28137 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01853631 | Feb 2014 → Dec 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19.CAR/28137 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01853631 ↗ |
| Action | Deplete | “The investigators believe that if they add an extra stimulating protein, called CD137, the cells will have a better chance of killing the lymphoma cells.” NCT01853631 ↗ |
| Route | Intravenous | “Patients will be given an injection of cells into the vein through an IV at the assigned dose.” NCT01853631 ↗ |